Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Holtzman

Showing results (451-460 of 554) with videos related to

Pageof 56
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2017
Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's diseaseRobert J Andrew, Celia G Fernandez, Molly Stanley, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 15, 2018
NIA-AA Research Framework: Toward a biological definition of Alzheimer's diseaseClifford R Jack, David A Bennett, Kaj Blennow, et al.
Nature Medicine|March 31, 2025
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's diseaseKanta Horie, Gemma Salvadó, Rama K Koppisetti, et al.
Plos One|January 26, 2011
Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's diseaseRichard J Perrin, Rebecca Craig-Schapiro, James P Malone, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 20, 2024
APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer diseaseRosemary J Jackson, Megan S Keiser, Jonah C Meltzer, et al.
Medrxiv : the Preprint Server for Health Sciences|July 28, 2023
Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer's diseaseGemma Salvadó, Kanta Horie, Nicolas R Barthélemy, et al.
Biological Psychiatry|November 2, 2010
YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's diseaseRebecca Craig-Schapiro, Richard J Perrin, Catherine M Roe, et al.
Annals of Neurology|June 18, 2011
Alternative processing of γ-secretase substrates in common forms of mild cognitive impairment and Alzheimer's disease: evidence for γ-secretase dysfunctionSaori Hata, Sayaka Fujishige, Yoichi Araki, et al.
Neurology. Genetics|April 22, 2021
African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic VariantsSuzanne E Schindler, Carlos Cruchaga, Amulya Joseph, et al.
Cell|August 13, 2017
TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's DiseaseTyler K Ulland, Wilbur M Song, Stanley Ching-Cheng Huang, et al.
Pageof 56

Showing results (451-460 of 554) with videos related to

Sort By:
Pageof 56
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2017
Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's diseaseRobert J Andrew, Celia G Fernandez, Molly Stanley, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 15, 2018
NIA-AA Research Framework: Toward a biological definition of Alzheimer's diseaseClifford R Jack, David A Bennett, Kaj Blennow, et al.
Nature Medicine|March 31, 2025
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's diseaseKanta Horie, Gemma Salvadó, Rama K Koppisetti, et al.
Plos One|January 26, 2011
Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's diseaseRichard J Perrin, Rebecca Craig-Schapiro, James P Malone, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 20, 2024
APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer diseaseRosemary J Jackson, Megan S Keiser, Jonah C Meltzer, et al.
Medrxiv : the Preprint Server for Health Sciences|July 28, 2023
Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer's diseaseGemma Salvadó, Kanta Horie, Nicolas R Barthélemy, et al.
Biological Psychiatry|November 2, 2010
YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's diseaseRebecca Craig-Schapiro, Richard J Perrin, Catherine M Roe, et al.
Annals of Neurology|June 18, 2011
Alternative processing of γ-secretase substrates in common forms of mild cognitive impairment and Alzheimer's disease: evidence for γ-secretase dysfunctionSaori Hata, Sayaka Fujishige, Yoichi Araki, et al.
Neurology. Genetics|April 22, 2021
African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic VariantsSuzanne E Schindler, Carlos Cruchaga, Amulya Joseph, et al.
Cell|August 13, 2017
TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's DiseaseTyler K Ulland, Wilbur M Song, Stanley Ching-Cheng Huang, et al.
Pageof 56